How many patients do you manage with moderate-to-severe atopic dermatitis?

On a scale from 1-10 (10 being extremely excited), where would you rate your level of excitement for rezpegaldesleukin as a treatment for moderate-to-severe atopic dermatitis?

Rezpegaldesleukin achieved statistically significant improvements across all primary and key secondary endpoints at week 16, including EASI, vIGA-AD, and Itch NRS. How do these results position IL-2 pathway agonism as a potential new mechanism in the treatment of moderate-to-severe atopic dermatitis?

The study showed rapid onset of action, with clinical benefit emerging after only a few doses. How clinically meaningful is this early response, and how might it compare to the onset timelines observed with currently approved biologics or JAK inhibitors?

Patients crossing over from placebo to high-dose rezpegaldesleukin demonstrated deepening responses—EASI-75 increasing to 62% and vIGA-AD 0/1 to 38% by week 24. What does this durability and deepening of effect suggest about the potential advantages of extended Treg stimulation?

High-dose rezpegaldesleukin showed strong patient-reported outcome improvements, including a 72% DLQI response and 67% ADCT response. How important are these quality-of-life metrics in assessing the real-world value of emerging therapies for atopic dermatitis?

The safety profile over the 16-week induction period was consistent with previous studies, with no increase in serious adverse events versus placebo. Given the chronic nature of atopic dermatitis, how do you interpret these findings in terms of long-term tolerability and future maintenance regimens?